IT1238231B - Impiego di immunomodulanti come agenti sinergici di chemioterapici nella terapia dei tumori - Google Patents

Impiego di immunomodulanti come agenti sinergici di chemioterapici nella terapia dei tumori

Info

Publication number
IT1238231B
IT1238231B IT02272589A IT2272589A IT1238231B IT 1238231 B IT1238231 B IT 1238231B IT 02272589 A IT02272589 A IT 02272589A IT 2272589 A IT2272589 A IT 2272589A IT 1238231 B IT1238231 B IT 1238231B
Authority
IT
Italy
Prior art keywords
immunomodulants
chemotherapy
cancer therapy
synergic agents
synergic
Prior art date
Application number
IT02272589A
Other languages
English (en)
Other versions
IT8922725A0 (it
IT8922725A1 (it
Original Assignee
Consiglio Nazionale Ricerche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consiglio Nazionale Ricerche filed Critical Consiglio Nazionale Ricerche
Priority to IT02272589A priority Critical patent/IT1238231B/it
Publication of IT8922725A0 publication Critical patent/IT8922725A0/it
Priority to EP90123297A priority patent/EP0433765A1/en
Priority to JP2411343A priority patent/JPH049338A/ja
Publication of IT8922725A1 publication Critical patent/IT8922725A1/it
Application granted granted Critical
Publication of IT1238231B publication Critical patent/IT1238231B/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/32—Thymopoietins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
IT02272589A 1989-12-18 1989-12-18 Impiego di immunomodulanti come agenti sinergici di chemioterapici nella terapia dei tumori IT1238231B (it)

Priority Applications (3)

Application Number Priority Date Filing Date Title
IT02272589A IT1238231B (it) 1989-12-18 1989-12-18 Impiego di immunomodulanti come agenti sinergici di chemioterapici nella terapia dei tumori
EP90123297A EP0433765A1 (en) 1989-12-18 1990-12-05 The use of immunomodulants as synergistic agents of chemotherapeutics in tumor therapy
JP2411343A JPH049338A (ja) 1989-12-18 1990-12-18 腫瘍治療における化学療法薬の共働剤としての免疫調整剤の使用方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT02272589A IT1238231B (it) 1989-12-18 1989-12-18 Impiego di immunomodulanti come agenti sinergici di chemioterapici nella terapia dei tumori

Publications (3)

Publication Number Publication Date
IT8922725A0 IT8922725A0 (it) 1989-12-18
IT8922725A1 IT8922725A1 (it) 1991-06-18
IT1238231B true IT1238231B (it) 1993-07-12

Family

ID=11199710

Family Applications (1)

Application Number Title Priority Date Filing Date
IT02272589A IT1238231B (it) 1989-12-18 1989-12-18 Impiego di immunomodulanti come agenti sinergici di chemioterapici nella terapia dei tumori

Country Status (3)

Country Link
EP (1) EP0433765A1 (it)
JP (1) JPH049338A (it)
IT (1) IT1238231B (it)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6410010B1 (en) 1992-10-13 2002-06-25 Board Of Regents, The University Of Texas System Recombinant P53 adenovirus compositions
US5747469A (en) 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
WO1992015680A1 (en) 1991-03-06 1992-09-17 Board Of Regents, The University Of Texas System Methods and compositions for the selective inhibition of gene expression
CN1094310A (zh) * 1992-12-15 1994-11-02 托马斯·C·梅里根 人体免疫缺陷性病毒感染用组合式化学疗法
US5632983A (en) * 1994-11-17 1997-05-27 University Of South Florida Method for treating secondary immunodeficiency
EP0968284B1 (en) 1996-11-20 2006-12-13 Introgen Therapeutics, Inc. An improved method for the production and purification of adenoviral vectors
US7732129B1 (en) 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
US6084687A (en) * 1996-12-25 2000-07-04 Fuji Xerox Co., Ltd. Image processing system, drawing system, drawing method, medium, printer, and image display unit
US6787132B1 (en) 1997-12-04 2004-09-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Combined chemo-immunotherapy with liposomal drugs and cytokines
AU756109B2 (en) * 1997-12-04 2003-01-02 Hadasit Medical Research Services & Development Company Ltd Methods for antitumor therapy
US6689600B1 (en) 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
US20070025958A1 (en) 2000-10-27 2007-02-01 Hadden John W Vaccine immunotherapy
US6977072B2 (en) 2000-10-27 2005-12-20 Irx Therapeutics, Inc. Vaccine immunotherapy for immune suppressed patients
UA77999C2 (en) * 2001-12-10 2007-02-15 Thymosin-alpha 1 for treatment of malignant glioblastoma
WO2006052302A2 (en) 2004-11-03 2006-05-18 Introgen Therapeutics Inc. Method of producing and purifying adenoviral vectors
US8329160B2 (en) 2007-06-15 2012-12-11 Hi-Stem Interferon alpha sequential regimen for treating cancers
US20100204158A1 (en) * 2007-09-11 2010-08-12 Dorian Bevec Combination of splenopentin and thymopentin and the use thereof in medicine
AU2008303932A1 (en) * 2007-09-11 2009-04-02 Mondobiotech Laboratories Ag Use of BPP-B as a therapeutic agent
KR20100056516A (ko) * 2007-09-11 2010-05-27 몬도바이오테크 래보래토리즈 아게 가스트린－１ 및 ｇ－ｐｅｎ－ｇｒｇｄｓｐｃａ의 치료적 용도
AU2008329741B2 (en) 2007-11-28 2013-09-12 Irx Therapeutics, Inc. Method of increasing immunological effect
ES2679043T3 (es) 2009-05-15 2018-08-21 Irx Therapeutics, Inc. Inmunoterapia de vacuna
US9333238B2 (en) 2009-12-08 2016-05-10 Irx Therapeutics, Inc. Method of immunotherapy for treament of human papillomavirus infection
JP6948685B2 (ja) * 2016-11-04 2021-10-13 国立大学法人金沢大学 抗癌作用増強剤及び癌治療支援方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4978332A (en) * 1987-09-28 1990-12-18 Matrix Pharmaceutical, Inc. Treatments employing vasoconstrictive substances in combination with cytotoxic agents for introduction into cellular lesion areas
CA2010511A1 (en) * 1989-03-01 1990-09-01 Roberto L. Ceriani Method of enhancing cancer therapy by administration of unsaturated fatty acids

Also Published As

Publication number Publication date
JPH049338A (ja) 1992-01-14
EP0433765A1 (en) 1991-06-26
IT8922725A0 (it) 1989-12-18
IT8922725A1 (it) 1991-06-18

Similar Documents

Publication Publication Date Title
IT1238231B (it) Impiego di immunomodulanti come agenti sinergici di chemioterapici nella terapia dei tumori
IT1227260B (it) Dieteri utilizzabili nella preparazione di catalizzatori ziegler-natta
IT1298470B1 (it) Composti impiegati nella prevenzione del cancro della mammella e uso degli stessi
ITMI911096A0 (it) Composti di sintesi atti all'impiego nella terapia delle infezioni da rhinovirus
EP0133766A3 (en) Coumarin derivatives, pharmaceutical compositions containing the same, and the use thereof in the treatment of cancer
IT8468281A0 (it) Proglumide e composizioni farmaceutiche che la contengono per l impiego nella terapia di affezioni neoplastiche
ITRM910730A0 (it) Composizioni farmaceutiche, per uso topico, contenenti "scavengers" diradicali liberi dell'ossigeno e antibatterici, indicate nella terapia dei tessuti superficiali
IT1123142B (it) Uso di glicerilfosforil derivati nella terapia di dislipemie ed epatiti,e composizioni farmaceutiche relative
GB9106170D0 (en) New compounds for use in the treatment of cancer
IT1232584B (it) Miglioramenti nella struttura di cassetti per mobili
IT1170238B (it) Impiego di ibuprofene e flurbiprofene nella cura dell'erpete
IT8367899A0 (it) Composizione per la cura dei tumori maligni in particolare sugli animali
IT1188704B (it) Derivati insaturi cicloalifatici,loro procedimenti di prepatazione e loro impiego in terapia e in cosmetica
IT8109468A0 (it) Uso di derivati mercaptoacilsostituiti della prolina nella terapia delle cefalee essenziali
ITMI911122A0 (it) Composizioni per la terapia topica delle ustioni
KR930703331A (ko) 비사이클로폴리아자매크로사이클로카복실산 착체, 그의 결합체, 그의 제조방법 및 방사성 약제로서의 그의 용도
IT1276321B1 (it) Derivati del carbossimetilidenecicloptimmidazolo procedimento di fabbricazione dei derivati e agenti terapeutici che contengono
EP0810866A4 (en) USE IN THE TREATMENT OF CANCERS OF ORGANOMETALLIC COMPOUNDS OF ACID-SENSITIVE TRANSITION METALS
IT1190782B (it) Derivati diossazabiciclici,loro procedimento di preparazione e loro applicazione in terapia
FI972637A0 (fi) K-ryhmän vitamiinin käyttö lisäkilpirauhasen liikatoiminnan hoitoon
IT9022513A0 (it) Impiego dell'eptastigmina nella terapia dell'ictus cerebrale.
IT8847913A0 (it) Uso di enalapril nel trattamento terapeutico delle cefalee essenziali
IT1194359B (it) Applicazione terapeutica del mazindolo nella malattia di parkinson
IT7927848A0 (it) Derivati 1-carbammoil-5-fluorouracilici emetodo di impiego degli stessi nella terapia dei tumori.
ITMI931369A0 (it) Composizione farmaceutica per la terapia e la profilassi tumorale

Legal Events

Date Code Title Description
0001 Granted
TA Fee payment date (situation as of event date), data collected since 19931001

Effective date: 19951229